MXPA03003161A - Formas de profarmaco modificadas de ap/amp. - Google Patents

Formas de profarmaco modificadas de ap/amp.

Info

Publication number
MXPA03003161A
MXPA03003161A MXPA03003161A MXPA03003161A MXPA03003161A MX PA03003161 A MXPA03003161 A MX PA03003161A MX PA03003161 A MXPA03003161 A MX PA03003161A MX PA03003161 A MXPA03003161 A MX PA03003161A MX PA03003161 A MXPA03003161 A MX PA03003161A
Authority
MX
Mexico
Prior art keywords
prodrug forms
ocf3
och3
modified prodrug
modified
Prior art date
Application number
MXPA03003161A
Other languages
English (en)
Inventor
Terrence W Doyle
Original Assignee
Vion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vion Pharmaceuticals Inc filed Critical Vion Pharmaceuticals Inc
Publication of MXPA03003161A publication Critical patent/MXPA03003161A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se relaciona con compuestos de acuerdo con la estructura de la siguiente formula (I) en donde R es H o CH3; R2 es fosfato el cual puede ser un acido libre o sal; R3 es H, F, C1, Br, I, OCH3, OCF3, CF3 o un grupo alquilo de 1 a 3 atomos de carbono; R4 es H, F, C1, Br, I, OCH3, OCF3 o CF3; y R5 y R6 son cada uno independientemente H, F, C1, Br, I, OCH3, OCF3 o CF3, con la condicion de que cualquiera dos de R3, R4, R5 o R6 sean diferentes de H, los otros dos de R3, R4, R5, o R6 son H, los cuales se pueden utilizar para tratar neoplasia, que incluye cancer.
MXPA03003161A 2000-10-13 2001-10-15 Formas de profarmaco modificadas de ap/amp. MXPA03003161A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24052900P 2000-10-13 2000-10-13
PCT/US2001/032085 WO2002030424A1 (en) 2000-10-13 2001-10-15 Modified prodrug forms of ap/amp

Publications (1)

Publication Number Publication Date
MXPA03003161A true MXPA03003161A (es) 2004-05-05

Family

ID=22906907

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03003161A MXPA03003161A (es) 2000-10-13 2001-10-15 Formas de profarmaco modificadas de ap/amp.

Country Status (13)

Country Link
US (1) US6458816B1 (es)
EP (1) EP1335726B1 (es)
JP (1) JP4162994B2 (es)
KR (1) KR20030063360A (es)
CN (1) CN1224388C (es)
AT (1) ATE510539T1 (es)
AU (2) AU1172502A (es)
BR (1) BR0114598A (es)
CA (1) CA2423220C (es)
HK (1) HK1058005A1 (es)
MX (1) MXPA03003161A (es)
RU (1) RU2003113538A (es)
WO (1) WO2002030424A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085358A2 (en) * 2001-04-20 2002-10-31 Vion Pharmaceuticals, Inc. Antiviral agents and methods of treating viral infections
JP2007515945A (ja) * 2003-05-30 2007-06-21 ロゼッタ インファーマティックス エルエルシー キネシン活性の調節因子を同定するための方法
US6855695B2 (en) 2003-06-13 2005-02-15 Vion Pharmaceuticals, Inc. Water-soluble SHPs as novel alkylating agents
JP5095216B2 (ja) 2003-11-14 2012-12-12 ローラス セラピューティクス インコーポレーテッド アリールイミダゾールおよびその抗癌剤としての使用
WO2005055952A2 (en) * 2003-12-08 2005-06-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic anti-cancer compositions
US7605137B2 (en) 2004-03-26 2009-10-20 Vion Pharmaceuticals, Inc. Combination therapy comprising cloretazine
EP1793823B1 (en) * 2004-09-21 2012-08-08 Vion Pharmaceuticals, Inc. Phosphate containing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents
CA2611032C (en) * 2005-05-25 2012-01-17 Genesense Technologies Inc. 2-indolyl imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120045433A1 (en) * 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
WO2014153464A2 (en) 2013-03-20 2014-09-25 Lorus Therapeutics Inc. 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
KR20160058960A (ko) 2013-10-04 2016-05-25 압토스 바이오사이언시스 인코포레이티드 암을 치료하기 위한 조성물과 방법
EP3703685A4 (en) 2017-10-30 2021-07-28 Aptose Biosciences Inc. ARYLIMIDAZOLES FOR CANCER TREATMENT

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767134A (en) * 1997-05-15 1998-06-16 Vion Pharmaceuticals, Inc. Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP
WO2002085358A2 (en) * 2001-04-20 2002-10-31 Vion Pharmaceuticals, Inc. Antiviral agents and methods of treating viral infections

Also Published As

Publication number Publication date
CN1468102A (zh) 2004-01-14
US6458816B1 (en) 2002-10-01
US20020119955A1 (en) 2002-08-29
AU1172502A (en) 2002-04-22
ATE510539T1 (de) 2011-06-15
EP1335726A1 (en) 2003-08-20
JP4162994B2 (ja) 2008-10-08
HK1058005A1 (en) 2004-04-30
JP2004510818A (ja) 2004-04-08
EP1335726A4 (en) 2009-03-25
CN1224388C (zh) 2005-10-26
CA2423220A1 (en) 2002-04-18
RU2003113538A (ru) 2004-11-10
WO2002030424A1 (en) 2002-04-18
EP1335726B1 (en) 2011-05-25
KR20030063360A (ko) 2003-07-28
CA2423220C (en) 2012-01-03
AU2002211725B2 (en) 2005-06-30
BR0114598A (pt) 2003-07-01

Similar Documents

Publication Publication Date Title
MXPA03003161A (es) Formas de profarmaco modificadas de ap/amp.
NL350075I2 (es)
JO2372B1 (en) Source drugs of 4-phenylpyridine derivatives
DK1485359T3 (da) Natriumkanalblokkere
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
SI1585739T1 (sl) Substituirani arilciklopropilacetamidi kot aktivatorji glukokinaze
BG106585A (en) Kinase inhibitors as therapeutic agents
IL180428A0 (en) Novel flame-retardant polystyrenes
MXPA02011370A (es) Iminoazinas substituidas.
WO2004084812A3 (en) Tamandarin analogs and fragments thereof and methods of making and using
HRP20050082A2 (en) 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
MY136824A (en) Substituted benzoxazinones and uses thereof
MX2023009045A (es) Derivados novedosos de pirimidin-2-il sulfonamida.
ES472290A1 (es) Un procedimiento para preparar un compuesto de benceno di- sustituido en orto
NO20022977D0 (no) Substituerte homopiperidinylbenzimidazolanaloger som fundiske relaksanter
BRPI0411664A (pt) composição oral antiplaca aquosa estável
MXPA03005374A (es) Carbazoles antitumorales.
ATE276259T1 (de) Dihydroporphyrinderivate und ihre verwendung
MY123373A (en) 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
PT1651596E (pt) Novos derivados de 4,4?-ditiobis-(3-aminobutano-1-sulfonatos) e composições que os contêm
MXPA05003909A (es) Compuestos de benzopiranona, composiciones de los mismos, y metodos para el tratamiento o prevencion del cancer.
CY1107515T1 (el) Συνθεση ενδιαμεσων χρησιμων στην παρασκευη τρικυκλικων ενωσεων
GB0103046D0 (en) Organic Compounds
MXPA05003881A (es) Preparacion de compuestos triazospiro.